NCT01615042View on ClinicalTrials.gov

Phase I Study of Lenalidomide in Patients With Acute Leukemia

PHASE1TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

Acute Leukemia

Interventions

DRUG

Lenalidomide

Oral capsule, daily, 50mg-100mg, one cycle (21 days)

Trial Locations (1)

95817

University of California Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Celgene

INDUSTRY

lead

Mehrdad Abedi, MD

OTHER